MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. (Q54270566)

27 May 2018

title

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. (English)

1 reference

27 May 2018

author

Miguel Alcoceba

11

1 reference

27 May 2018

Norma C. Gutiérrez

18

1 reference

27 May 2018

Ramón García-Sanz

21

1 reference

27 May 2018

Elena Sebastián

object named as

E Sebastián

2

0 references

M. Carmen Chillón

3

object named as

M C Chillón

1 reference

27 May 2018

author name string

C Jiménez

1

1 reference

27 May 2018

P Giraldo

4

1 reference

27 May 2018

J Mariano Hernández

5

1 reference

27 May 2018

F Escalante

6

1 reference

27 May 2018

T J González-López

7

1 reference

27 May 2018

C Aguilera

8

1 reference

27 May 2018

A G de Coca

9

1 reference

27 May 2018

I Murillo

10

1 reference

27 May 2018

A Balanzategui

12

1 reference

27 May 2018

M E Sarasquete

13

1 reference

27 May 2018

R Corral

14

1 reference

27 May 2018

L A Marín

15

1 reference

27 May 2018

B Paiva

16

1 reference

27 May 2018

E M Ocio

17

1 reference

27 May 2018

M González

19

1 reference

27 May 2018

J F San Miguel

20

1 reference

27 May 2018

publication date

28 February 2013

1 reference

27 May 2018

published in

Leukemia

1 reference

27 May 2018

volume

27

1 reference

27 May 2018

issue

8

1 reference

27 May 2018

page(s)

1722-1728

1 reference

27 May 2018

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

The incidence and survival of Waldenström's Macroglobulinaemia in South East England

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Molecular pathogenesis of Waldenstrom's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Oncogenically active MYD88 mutations in human lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Analysis of the coding genome of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2013.62

1 reference

7 January 2021

How I treat Waldenström macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Dangerous small B-cell clones.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

MYD88 L265P somatic mutation in IgM MGUS

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Absence of MYD88 gene mutation in acute leukemias and multiple myelomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Immunoglobulin class-switch DNA recombination: induction, targeting and beyond

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

CD27 in defining memory B-cell origins in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.62

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.62

1 reference

27 May 2018

1 reference

27 May 2018